Skip to main content
Top
Published in: Arthritis Research & Therapy 2/2009

Open Access 01-04-2009 | Research article

High frequency of corticosteroid and immunosuppressive therapy in patients with systemic sclerosis despite limited evidence for efficacy

Authors: Nicolas Hunzelmann, Pia Moinzadeh, Ekkehard Genth, Thomas Krieg, Walter Lehmacher, Inga Melchers, Michael Meurer, Ulf Müller-Ladner, Thorsten M Olski, Christiane Pfeiffer, Gabriela Riemekasten, Eckhard Schulze-Lohoff, Cord Sunderkoetter, Manfred Weber, the German Network for Systemic Scleroderma Centers

Published in: Arthritis Research & Therapy | Issue 2/2009

Login to get access

Abstract

Introduction

In systemic sclerosis (SSc) little evidence for the effectiveness of anti-inflammatory and immunosuppressive therapy exists. The objective of this study was to determine the extent to which SSc patients are treated with corticosteroids and immunosuppressive agents.

Methods

Data on duration and dosage of corticosteroids and on the type of immunosuppressive agent were analyzed from 1,729 patients who were registered in the German Network for Systemic Scleroderma (DNSS).

Results

A total 41.3% of all registered SSc patients was treated with corticosteroids. Corticosteroid use was reported in 49.1% of patients with diffuse cutaneous SSc and 31.3% of patients with limited cutaneous SSc (P < 0.0001). Among patients with overlap disease characteristics, 63.5% received corticosteroids (P < 0.0001 vs. limited cutaneous SSc). A total 16.1% of the patients received corticosteroids with a daily dose ≥ 15 mg prednisone equivalent. Immunosuppressive therapy was prescribed in 35.8% of patients. Again, among those patients with overlap symptoms, a much higher proportion (64.1%) was treated with immunosuppressive agents, compared with 46.4% of those with diffuse cutaneous SSc sclerosis and 22.2% of those with limited cutaneous SSc (P < 0.0001). The most commonly prescribed drugs were methotrexate (30.5%), cyclophosphamide (22.2%), azathioprine (21.8%) and (hydroxy)chloroquine (7.2%). The use of these compounds varied significantly between medical subspecialties.

Conclusions

Despite limited evidence for the effectiveness of corticosteroids and immunosuppressive agents in SSc, these potentially harmful drugs are frequently prescribed to patients with all forms of SSc. Therefore, this study indicates the need to develop and communicate adequate treatment recommendations.
Appendix
Available only for authorised users
Literature
1.
go back to reference Denton CP, Black CM: Scleroderma – clinical and pathological advances. Best Pract Res Clin Rheumatol. 2004, 18: 271-290.CrossRefPubMed Denton CP, Black CM: Scleroderma – clinical and pathological advances. Best Pract Res Clin Rheumatol. 2004, 18: 271-290.CrossRefPubMed
2.
go back to reference White B, Bauer EA, Goldsmith LA: Guidelines for clinical trials in systemic sclerosis (scleroderma). I. Disease modifying interventions. The American College of Rheumatology Committee on Design and Outcomes in Clinical Trials in Systemic sclerosis. Arthritis Rheum. 1995, 38: 351-360. 10.1002/art.1780380309.CrossRefPubMed White B, Bauer EA, Goldsmith LA: Guidelines for clinical trials in systemic sclerosis (scleroderma). I. Disease modifying interventions. The American College of Rheumatology Committee on Design and Outcomes in Clinical Trials in Systemic sclerosis. Arthritis Rheum. 1995, 38: 351-360. 10.1002/art.1780380309.CrossRefPubMed
3.
go back to reference White B, Moore WC, Wigley FM, Xiao HQ, Wise RA: Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med. 2000, 132: 947-954.CrossRefPubMed White B, Moore WC, Wigley FM, Xiao HQ, Wise RA: Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med. 2000, 132: 947-954.CrossRefPubMed
4.
go back to reference Steen VD, Medsger TA: Case–control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum. 1998, 41: 1613-1619. 10.1002/1529-0131(199809)41:9<1613::AID-ART11>3.0.CO;2-O.CrossRefPubMed Steen VD, Medsger TA: Case–control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum. 1998, 41: 1613-1619. 10.1002/1529-0131(199809)41:9<1613::AID-ART11>3.0.CO;2-O.CrossRefPubMed
5.
go back to reference Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, Arriola E, Silver R, Strange C, Bolster M, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel DE, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, et al: Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006, 354: 2655-2666. 10.1056/NEJMoa055120.CrossRefPubMed Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, Arriola E, Silver R, Strange C, Bolster M, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel DE, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, et al: Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006, 354: 2655-2666. 10.1056/NEJMoa055120.CrossRefPubMed
6.
go back to reference Hoogen van den FH, Boerbooms AM, Swaak AJ, Rasker JJ, van Lier HJ, Putte van de LB: Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol. 1996, 35: 364-372. 10.1093/rheumatology/35.4.364.CrossRefPubMed Hoogen van den FH, Boerbooms AM, Swaak AJ, Rasker JJ, van Lier HJ, Putte van de LB: Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol. 1996, 35: 364-372. 10.1093/rheumatology/35.4.364.CrossRefPubMed
7.
go back to reference Hunzelmann N, Genth E, Krieg T, Lehmacher W, Melchers I, Meurer M, Moinzadeh P, Müller-Ladner U, Pfeiffer C, Riemekasten G, Schulze-Lohoff E, Sunderkoetter C, Weber M, Worm M, Klaus P, Rubbert A, Steinbrink K, Grundt B, Hein R, Scharffetter-Kochanek K, Hinrichs R, Walker K, Szeimies RM, Karrer S, Müller A, Seitz C, Schmidt E, Lehmann P, Foeldvári I, Reichenberger F, et al: The registry of the German network for systemic scleroderma: frequency of disease subsets and patterns of organ involvement. Rheumatology (Oxford). 2008, 47: 1185-1192. 10.1093/rheumatology/ken179.CrossRef Hunzelmann N, Genth E, Krieg T, Lehmacher W, Melchers I, Meurer M, Moinzadeh P, Müller-Ladner U, Pfeiffer C, Riemekasten G, Schulze-Lohoff E, Sunderkoetter C, Weber M, Worm M, Klaus P, Rubbert A, Steinbrink K, Grundt B, Hein R, Scharffetter-Kochanek K, Hinrichs R, Walker K, Szeimies RM, Karrer S, Müller A, Seitz C, Schmidt E, Lehmann P, Foeldvári I, Reichenberger F, et al: The registry of the German network for systemic scleroderma: frequency of disease subsets and patterns of organ involvement. Rheumatology (Oxford). 2008, 47: 1185-1192. 10.1093/rheumatology/ken179.CrossRef
8.
go back to reference LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA, Rowell N, Wollheim F: Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988, 15: 202-205.PubMed LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA, Rowell N, Wollheim F: Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988, 15: 202-205.PubMed
9.
go back to reference Bennett RM: Scleroderma overlap syndrome. Rheum Dis Clin North Am. 1990, 16: 185-198.PubMed Bennett RM: Scleroderma overlap syndrome. Rheum Dis Clin North Am. 1990, 16: 185-198.PubMed
10.
go back to reference Pope JE: Scleroderma overlap syndromes. Curr Opin Rheumatol. 2002, 14: 704-710. 10.1097/00002281-200211000-00013.CrossRefPubMed Pope JE: Scleroderma overlap syndromes. Curr Opin Rheumatol. 2002, 14: 704-710. 10.1097/00002281-200211000-00013.CrossRefPubMed
11.
go back to reference Poormoghim H, Lucas M, Fertig N, Medsger TA: Systemic sclerosis sine scleroderma: demographic, clinical, and serologic features and survival in forty-eight patients. Arthritis Rheum. 2000, 43: 444-451. 10.1002/1529-0131(200002)43:2<444::AID-ANR27>3.0.CO;2-G.CrossRefPubMed Poormoghim H, Lucas M, Fertig N, Medsger TA: Systemic sclerosis sine scleroderma: demographic, clinical, and serologic features and survival in forty-eight patients. Arthritis Rheum. 2000, 43: 444-451. 10.1002/1529-0131(200002)43:2<444::AID-ANR27>3.0.CO;2-G.CrossRefPubMed
12.
13.
go back to reference Giordano M, Valentini G, Migliaresi S, Picillo U, Vatti M: Different antibody patterns and different prognoses in patients with scleroderma with various extent of skin sclerosis. J Rheumatol. 1986, 13: 911-916.PubMed Giordano M, Valentini G, Migliaresi S, Picillo U, Vatti M: Different antibody patterns and different prognoses in patients with scleroderma with various extent of skin sclerosis. J Rheumatol. 1986, 13: 911-916.PubMed
14.
go back to reference Alarcon GS: Unclassified or undifferentiated connective tissue disease. Baillieres Best Pract Res Clin Rheumatol. 2000, 14: 125-137. 10.1053/berh.1999.0081.CrossRefPubMed Alarcon GS: Unclassified or undifferentiated connective tissue disease. Baillieres Best Pract Res Clin Rheumatol. 2000, 14: 125-137. 10.1053/berh.1999.0081.CrossRefPubMed
15.
go back to reference LeRoy EC, Maricq HR, Kahaleh MB: Undifferentiated connective tissue syndromes. Arthritis Rheum. 1980, 23: 341-343. 10.1002/art.1780230312.CrossRefPubMed LeRoy EC, Maricq HR, Kahaleh MB: Undifferentiated connective tissue syndromes. Arthritis Rheum. 1980, 23: 341-343. 10.1002/art.1780230312.CrossRefPubMed
16.
go back to reference Delany AM, Brinckerhoff CE: Posttranscriptional regulation of collagenase and stromelysin gene expression by epidermal growth factor and dexamethason in cultured human fibroblasts. J Cell Biochem. 1992, 50: 400-410. 10.1002/jcb.240500409.CrossRefPubMed Delany AM, Brinckerhoff CE: Posttranscriptional regulation of collagenase and stromelysin gene expression by epidermal growth factor and dexamethason in cultured human fibroblasts. J Cell Biochem. 1992, 50: 400-410. 10.1002/jcb.240500409.CrossRefPubMed
17.
go back to reference Steen VD, Medsger TA: Long-term outcomes of scleroderma renal crisis. Ann Intern Med. 2000, 133: 600-603.CrossRefPubMed Steen VD, Medsger TA: Long-term outcomes of scleroderma renal crisis. Ann Intern Med. 2000, 133: 600-603.CrossRefPubMed
18.
go back to reference Pope JE, Bellamy N, Seibold JR, Baron M, Ellman M, Carette S, Smith CD, Chalmers IM, Hong P, O'Hanlon D, Kaminska E, Markland J, Sibley J, Catoggio L, Furst DE: A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum. 2001, 44: 1351-1358. 10.1002/1529-0131(200106)44:6<1351::AID-ART227>3.0.CO;2-I.CrossRefPubMed Pope JE, Bellamy N, Seibold JR, Baron M, Ellman M, Carette S, Smith CD, Chalmers IM, Hong P, O'Hanlon D, Kaminska E, Markland J, Sibley J, Catoggio L, Furst DE: A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum. 2001, 44: 1351-1358. 10.1002/1529-0131(200106)44:6<1351::AID-ART227>3.0.CO;2-I.CrossRefPubMed
19.
go back to reference Nadashkevich O, Davis P, Fritzler M, Kovalenko W: A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis. Clin Rheumatol. 2006, 25: 205-212. 10.1007/s10067-005-1157-y.CrossRefPubMed Nadashkevich O, Davis P, Fritzler M, Kovalenko W: A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis. Clin Rheumatol. 2006, 25: 205-212. 10.1007/s10067-005-1157-y.CrossRefPubMed
20.
go back to reference Silver RM, Warrick JH, Kinsella MB, Staudt LS, Baumann MH, Strange C: Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. J Rheumatol. 1993, 20: 838-844.PubMed Silver RM, Warrick JH, Kinsella MB, Staudt LS, Baumann MH, Strange C: Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. J Rheumatol. 1993, 20: 838-844.PubMed
21.
go back to reference Nihtyanova SI, Brough GM, Black CM, Denton CP: Mycophenolate mofetil in diffuse cutaneous systemic sclerosis: a retrospective analysis. Rheumatology. 2007, 46: 442-445. 10.1093/rheumatology/kel244.CrossRefPubMed Nihtyanova SI, Brough GM, Black CM, Denton CP: Mycophenolate mofetil in diffuse cutaneous systemic sclerosis: a retrospective analysis. Rheumatology. 2007, 46: 442-445. 10.1093/rheumatology/kel244.CrossRefPubMed
22.
go back to reference Clements PJ, Furst DE, Wong WK, Mayes M, White B, Wigley F, Weisman MH, Barr W, Moreland LW, Medsger TA, Steen V, Martin RW, Collier D, Weinstein A, Lally E, Varga J, Weiner S, Andrews B, Abeles M, Seibold JR: High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial. Arthritis Rheum. 1999, 42: 1194-1203. 10.1002/1529-0131(199906)42:6<1194::AID-ANR16>3.0.CO;2-7.CrossRefPubMed Clements PJ, Furst DE, Wong WK, Mayes M, White B, Wigley F, Weisman MH, Barr W, Moreland LW, Medsger TA, Steen V, Martin RW, Collier D, Weinstein A, Lally E, Varga J, Weiner S, Andrews B, Abeles M, Seibold JR: High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial. Arthritis Rheum. 1999, 42: 1194-1203. 10.1002/1529-0131(199906)42:6<1194::AID-ANR16>3.0.CO;2-7.CrossRefPubMed
23.
go back to reference Olski T, Hunzelmann N: Immunosuppressive and antifibrotic therapy of systemic sclerosis. Expert Rev Dermatol. 2007, 2: 203-215. 10.1586/17469872.2.2.203.CrossRef Olski T, Hunzelmann N: Immunosuppressive and antifibrotic therapy of systemic sclerosis. Expert Rev Dermatol. 2007, 2: 203-215. 10.1586/17469872.2.2.203.CrossRef
24.
go back to reference Pope JE, Ouimet JM, Krizova A: Scleroderma treatment differs between experts and general rheumatologists. Arthritis Rheum. 2006, 55: 138-145. 10.1002/art.21714.CrossRefPubMed Pope JE, Ouimet JM, Krizova A: Scleroderma treatment differs between experts and general rheumatologists. Arthritis Rheum. 2006, 55: 138-145. 10.1002/art.21714.CrossRefPubMed
Metadata
Title
High frequency of corticosteroid and immunosuppressive therapy in patients with systemic sclerosis despite limited evidence for efficacy
Authors
Nicolas Hunzelmann
Pia Moinzadeh
Ekkehard Genth
Thomas Krieg
Walter Lehmacher
Inga Melchers
Michael Meurer
Ulf Müller-Ladner
Thorsten M Olski
Christiane Pfeiffer
Gabriela Riemekasten
Eckhard Schulze-Lohoff
Cord Sunderkoetter
Manfred Weber
the German Network for Systemic Scleroderma Centers
Publication date
01-04-2009
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 2/2009
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar2634

Other articles of this Issue 2/2009

Arthritis Research & Therapy 2/2009 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.